The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Wednesday, April 2nd, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.50-$8.50 per share. The ...

DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO ...

The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

Hinge Health, Inc. targets a $326B market with innovative musculoskeletal care solutions. Click here to find out more about the upcoming HNGE stock IPO.

Many experts - be they venture capitalists or private equity investprs - shared their advice to biotech entrepreneurs navigating a tough funding envornment.

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a ...